The majority of drugs used to treat asthma today are the same ones that were used 50 years ago. Tissue-level model of human airway musculature could pave way for patient-specific asthma treatments
New drugs are urgently needed to treat this chronic respiratory disease, which causes nearly 25 million people in the United States alone to wheeze, cough, and find it difficult at best to take a deep breath.
But finding new treatments is tough: asthma is a patient-specific disease, so what works for one person doesn’t necessarily work for another, and the animal models traditionally used to test new drug candidates often fail to mimic human responses–costing tremendous money and time.
Hope for healthier airways may be on the horizon thanks to a Harvard University team that has developed a human airway muscle-on-a-chip that could be used to test new drugs because it accurately mimics the way smooth muscle contracts in the human airway, under normal circumstances and when exposed to asthma triggers. As reported in the journal Lab on a Chip, it also offers a window into the cellular and even subcellular responses within the tissue during an asthmatic event.
“Every year asthma costs many tens of billions of dollars, significant productivity due to lost work and school days, and even lives,” said senior author Kevin Kit Parker, Ph.D., a Core Faculty member at Harvard’s Wyss Institute for Biologically Inspired Engineering and Tarr Family Professor of Bioengineering and Applied Physics at the Harvard School of Engineering and Applied Sciences (SEAS). Parker leads development of the Wyss Institute’s heart-on-a-chip technology as well and is specifically interested in diseases that affect children. “We were thrilled with how well the chip recapitulated the functioning of the human airway.”
The chip, a soft polymer well that is mounted on a glass substrate, contains a planar array of microscale, engineered human airway muscles, designed to mimic the laminar structure of the muscular layers of the human airway.
To mimic a typical allergic asthma response, the team first introduced interleukin-13 (IL-13) to the chip. IL-13 is a natural protein often found in the airway of asthmatic patients that mediates the response of smooth muscle to an allergen.
Then they introduced acetylcholine, a neurotransmitter that causes smooth muscle to contract. Sure enough, the airway muscle on the chip hypercontracted – and the soft chip curled up – in response to higher doses of the neurotransmitter.
They achieved the reverse effect as well and triggered the muscle to relax using drugs called ?-agonists, which are used in inhalers.
Significantly, they were able to measure the contractile stress of the muscle tissue as it responded to varying doses of the drugs, said lead author Alexander Peyton Nesmith, a Ph.D./M.D. student at Harvard SEAS and the University of Alabama at Birmingham. “Our chip offers a simple, reliable and direct way to measure human responses to an asthma trigger,” he said.
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Asthma led Gian Villante to two-month quarantine before rebookingon June 27, 2020 at 11:00 am
UFC heavyweight Gian Villante talks about the circumstances that led him to cancel his previously booked fight against Ben Rothwell at UFC 249 and return at UFC on ESPN 12 opposite Maurice Greene.
- Am I having an asthma attack? How to tell and what to do about iton June 26, 2020 at 12:29 pm
When you have an asthma attack, symptoms like coughing or having trouble breathing can become severe and may even be deadly if you are not properly treated. Here's how to know if you are having an ...
- CDC: Pregnancy, obesity, asthma included in risk factors for more severe COVID-19 caseson June 26, 2020 at 10:29 am
The Centers for Disease Control and Prevention issued new guidelines Thursday aimed at better identifying those who could be at greater risk of having a severe case of the COVID-19 virus.
- Experts Explain How ‘Godzilla’ Dust Cloud From Sahara Desert Could Affect Asthma, COVID-19 Suffererson June 25, 2020 at 9:32 pm
Medical experts revealed the various health hazards posed by the approaching massive dust cloud from the Sahara desert.
- Sahara Dust Health Impact: How Will Asthma, COVID-19 Sufferers Be Affected?on June 25, 2020 at 4:11 am
Studies have shown that breathing in dust particles can have an adverse impact on health, especially for those with pre-existing conditions. While much of the Saharan dust will remain high above the ...
- Asthma Leads Spending on Avoidable Pediatric Inpatient Stayson June 23, 2020 at 1:36 pm
Hospital charges for the treatment of children with asthma made up nearly half of all potentially avoidable pediatric inpatient costs in 2017.
- Global Asthma Clinical Trial Pipeline Highlights 2020 - ResearchAndMarkets.comon June 23, 2020 at 5:07 am
The "Global Asthma Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
- Asthma isn't a risk factor for hospitalization due to COVID-19, study showson June 19, 2020 at 2:13 pm
Using models that accounted for age, sex and ethnicity while adjusting for asthma risk factors such as smoking and obesity, the investigators found no meaningful difference in odds of hospitalization ...
- Asthma More Likely in Kids With Disabilities, Delayson June 19, 2020 at 1:43 pm
"This research has shown that it's not just clinicians or pediatricians that should be aware that children with disabilities and delays may also have other health problems. It's a ...
- Asthma and COPD Drugs 2020 Global Market to Reach US$ 43,444.72 Million And Growing At CAGR Of 7.90% By 2025on June 19, 2020 at 12:08 pm
The Global Asthma and COPD Drugs Market are anticipated to exhibit a CAGR of 7.90% to extend USD 43,444.72 Million during the review period. The market growth is propelled by the rising prevalence and ...
via Bing News